Solesence, Inc.

Good day and thank you for standing by. Welcome to the Solescence third quarter 2025 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To participate, you will need to press star 1 1 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, Simply press star 11 again. We ask that you please keep your questions to one and recue if needed. Please note this conference is being recorded. During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. This conference call may contain statements to reflect the company's current beliefs, and a number of important factors could cause actual results for future periods to differ materially from those stated on this call. These important factors include, without limitation, a decision of the customer to cancel purchase order or supplies, agreement, demand for an acceptance of the company's personal care ingredients, advanced materials and formulated products, changes in development and distribution relationships, the impact of competitive products and technology, possible disruption in commercial activities occasioned by public health issues, terrorist activity and armed conflict, and other risks indicated in the company's filings with the Securities and Exchange Commission. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, and other contingencies. I now hand the conference over to Kevin Curriton, President and Chief Executive Officer. Please go ahead, sir.

Thank you, Operator, and thank you to all of our investors, teammates, and friends joining us today. We have a lot to cover, so we appreciate your time, patience, and attention. Today is a meaningful moment in the history of Solescence. This is my first opportunity to speak with you since stepping into the role of President and Chief Executive Officer. I am truly honored to take on this responsibility and energized by the incredible talent of our team and the strong opportunities ahead to continue growing profitably with our brand partners. It is also a significant moment for another reason. Today marks Jess's final earnings call as a member of the Solescence leadership team. Many of you know that Jess and I began this journey together in 2012 when he brought me in to help chart a new path forward. The conversations we had during that interview process about transforming the business from a materials company into a product-focused organization became the foundation of what Solescence is today. Jess has been an exceptional partner to me and to all of us, working tirelessly to ensure we had the financial strength to grow, innovate, and establish ourselves as a leader in beauty innovation. With that, I'd like to turn it over to Jess for a few remarks. Jess?

Thanks, Kevin. Since this will be my final earnings call, I'd like to briefly touch on my time at Solescence and why now is the right time for Kevin to lead the company going forward. Over the past decade, Celestins pioneered the skin health and mineral-based beauty industry, establishing more than 90 globally issued patents across four technology platforms. By collaborating with our brand partners, the use of mineral-based active ingredients in beauty products has become more widespread. We're seeing more and more brands infuse their products with SPF technology. We've grown at a CAGR of greater than 7x as compared to our addressable market in the skincare, color cosmetics, and sun care cosmetics areas and have won eight awards for product and technology innovation so far and are sure to win more. Now, we're the industry leader in this space. And as I pass the torch to Kevin, we believe we can expand on this position for several reasons. First, the complexity and difficult logistics that go into creating these types of products means that our industry has substantial barriers to entry that limit the number of potential competitors. Second, we possess a unique mix of expertise, best-in-class technology, and manufacturing capabilities that very few can match. And third, Celestis will maintain the same relentless commitment to scientific excellence and innovation that has always driven us. As I've reflected on my time here, I couldn't be more gratified by what we've accomplished. The transformation of Celescence is a testament to the hard work and dedication of our team, and I'm grateful for having the opportunity to work alongside so many talented individuals. It has been no less than a privilege. This includes Kevin, with whom I've worked closely for over a decade. With his extensive industry experience, deep expertise and vision, I'm confident that he is the right person to lead Celestins into this next exciting era of growth. I'll now pass the call to Kevin, who will provide a summary of the quarter as well as the vision and outlook for the company. Kevin?